Tackling the Diversity of Triple-Negative Breast Cancer
Tackling the Diversity of Triple-Negative Breast Cancer
复制标题
DOI：
10.1158/1078-0432.ccr-13-0915
复制
发表时间：
2013-12-01
影响因子：
11.5
通讯作者：
Reis-Filho, Jorge S.
中科院分区：
文献类型：
--
作者：
Turner, Nicholas C.;Reis-Filho, Jorge S.
三阴性乳腺癌（TNBC）包括高度多样化的癌症集合。在这里，我们从基因表达亚型和遗传事件的角度来回顾这种多样性。TNBC的转录组学分析揭示了至少六种亚型，其中腔内雄激素受体（腔内AR）或分子大泌癌在三阴性疾病中形成了一个独特的组。与基因表达亚型不同，TNBC中描述了多种遗传事件，发现了许多潜在的靶向遗传事件，尽管频率相对较低。确定针对这些低频事件的治疗的临床效用的临床试验将需要大量的筛选工作来确定足够的患者。针对TNBC的多样性，三阴性疾病患者的临床研究需要将重点放在预先进行分子分层的分子定义亚群上，或者对分子定义亚群进行次要终点分析。这些方法对于实现tnbc患者精准医疗的潜力至关重要。临床癌症研究；19日(23日);6380 - 8。(c) 2013年aacr。
Triple-negative breast cancer (TNBC) comprises a highly diverse collection of cancers. Here, we review this diversity both in terms of gene expression subtypes and the repertoire of genetic events. Transcriptomic analyses of TNBC have revealed at least six subtypes, with the luminal androgen receptor (luminal AR) or molecular apocrine cancers forming a distinct group within triple-negative disease. Distinct from the gene expression subtypes, a diverse set of genetic events have been described in TNBC, with a number of potentially targetable genetic events found although all at relatively low frequency. Clinical trials to define the clinical utility of therapies targeting these low-frequency events will require substantial screening efforts to identify sufficient patients. Set against the diversity of TNBC, clinical studies of patients with triple-negative disease will need to be either focused on molecularly defined subsets with upfront molecular stratification, or powered for a secondary endpoint analysis of a molecularly defined subset. Such approaches will be crucial to realize the potential of precision medicine for patients with TNBCs. Clin Cancer Res; 19(23); 6380-8. (C) 2013 AACR.